Current share price for PNV : $1.015 0.02 (1.93%)+
Polynovo Limited (PNV), an ASX-listed company, is engaged in the development of medical devices for medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb.
| ASX Code | PNV |
| Website | http://polynovo.com |
| Industry/Sector | Health Care Supplies |
| Market Cap ($M) | 701 |
| PNV Share Price | $1.015 |
| Day High | $1.040 |
| Day Low | $1.000 |
| Last Close | $1.035 |
| PNV Share Price Movement | $0.02 ( 1.93% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Polynovo Limited (PNV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $13.21 | $1.90 | 152.00% | 101.60 | 0.00 | 0.00% | 0.0% |
| 2024A | $5.26 | $0.80 | -204.20% | 232.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$4.92 | -$0.70 | 300.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Ansell Limited (ANN) | $4,430M | 0.2270 | 0.0595 | 0.1435 | 16.5003 | 15.5740 | 13.6195 | 2.43% | 2.91% | 3.32% |
| Nanosonics Limited (NAN) | $1,001M | 0.5929 | 0.0000 | 0.0000 | 50.0747 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Polynovo Limited (PNV) | $715M | 1.5200 | 0.0000 | 0.0000 | 54.7619 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.43 | 53.70 | 8.42 | 0.00 |
| Market | 0.28 | 13.10 | 1.15 | 0.59 |
| Sector | 0.67 | 23.50 | 1.63 | 2.04 |
| Name | Position | Start Date |
|---|---|---|
| Dr Robyn Elliott | Non-Executive Director | 28 Oct 2019 |
| Mr Andrew Stuart Lumsden | Non-Executive Director | 4 Jun 2021 |
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | 13 May 2020 |
| Dr Charmaine Hilary Gittleson | Non-Executive Director | 1 Apr 2026 |
| Mr Robert Douglas | Non-Executive Director | 14 Oct 2025 |
| Mr Leon Hoare | Non-Executive Director, Non-Executive Chairman | 27 Jan 2016 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Mar 2026 | DOUGLAS, Robert | Buy | Indirect Shares | 151,000 | $0.930 | $140,430.000 |
| 25 Feb 2026 | HOARE, Leon | Buy | Indirect Shares | 30,000 | $0.936 | $28,071.920 |
| 24 Feb 2026 | LUMSDEN, Andrew | Buy | Indirect Shares | 100,000 | $0.914 | $91,364.160 |
See all changes in directors' interest & trades for Polynovo Limited (PNV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Swami Raote | Chief Executive Officer |
| Jan-Marcel Gielen | Company Secretary |
| Amy Demediuk | General Counsel ,Company Secretary |
| Date | Event |
|---|---|
| 19 February 2027 | Report (Interim) |
| 07 September 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
| 24 August 2026 | Report (Annual) |
| 24 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.